1. Introduction {#sec1}
===============

Peripheral T-cell lymphomas (PTCLs) represent approximately 10%--15% of all non-Hodgkin\'s lymphomas (NHLs) in Western countries \[[@B1]--[@B3]\]. Although the clinical appearance and the manifestation sites vary widely between the different subgroups, most PTCL share some characteristics. Most patients are of older age (median age \>60 years) and usually present with advanced stage disease \[[@B4], [@B5]\]. PTCLs in general show an aggressive course and most studies detect the T-cell phenotype as an independent negative prognostic factor \[[@B6]--[@B9]\]. Both, the international prognostic index (IPI) and the prognostic index for T-cell lymphomas (PITs) that also include the bone marrow involvement, have shown prognostic value in PTCL and determine the outcome of patients with nodal PTCL \[[@B10]--[@B13]\]. In addition, in retrospective studies further parameters like the expression of Ki-67, the level of *β* ~2~-microglobulin, and the detection of the Epstein-Barr virus (EBV) have been found to have some prognostic relevance in PTCL \[[@B14]--[@B16]\].

The prognosis of PTCL is poor with the exception of the ALK (anaplastic lymphoma kinase) expressing anaplastic large cell lymphoma (ALCL) with a more favourable outcome after conventional chemotherapy and the primary cutaneous T-cell lymphomas (CTCL) that usually show an indolent clinical course \[[@B17], [@B18]\]. In contrast, for the remaining PTCL the outcome following anthracycline-based chemotherapy is worse compared to aggressive B-cell lymphomas even regarding the pre-rituximab era with a median overall survival (OS) of 9 to 42 months \[[@B19]--[@B21]\].

So far, no accepted standard treatment could be defined for PTCL. This mainly results from a lack of PTCL-restricted randomised trials and the heterogeneity of most published series. Although the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOP-like regimen are widely used first-line, these protocols have never been established prospectively in PTCL and are rather adopted from treatment strategies for aggressive B-cell lymphomas. Even the role of anthracyclines in the first-line treatment of PTCL is controversial since a large retrospective international survey did not reveal a significant impact on OS \[[@B5]\].

To improve the treatment results in PTCL more aggressive strategies such as high-dose therapy with autologous stem cell transplantation (HDT-autoSCT) and allogeneic stem cell transplantation (alloSCT) seem attractive strategies in PTCL. In this paper the data on stem cell transplantation for PTCL will be discussed.

2. Autologous Stem Cell Transplantation {#sec2}
=======================================

2.1. Second-Line Therapy {#sec2.1}
------------------------

HDT-autoSCT has become the standard of care in relapsing and primary refractory high-grade B-cell lymphomas. In PTCL, prospective randomized studies on salvage HDT-autoSCT are lacking. To date, at least 16 retrospective studies, each including more than 15 patients have addressed this issue and are listed in [Table 1](#tab1){ref-type="table"} \[[@B22]--[@B37]\].

The cited studies were heterogeneous in terms of histological subgroups, patient characteristics, prognostic factors, myeloablative regimen, and duration of follow-up. In addition, some series included patients receiving upfront autoSCT and did not provide separate analyses for the patients treated in second line. Taken together, this strategy is feasible and safe with a low morbidity and mortality rate. The OS in these series ranged from 35% at 2 years to 70% at 5 years, respectively, and the disease-free survival (DFS) or event-free survival (EFS) from 28% at 2 years to 56% at 5 years, respectively. Although the earlier reports tend to show somewhat better results than the series published recently, when subgroup or matched control analyses were performed, the OS results for PTCL were equivalent to the long-term outcome in patients with aggressive B-cell lymphomas \[[@B22], [@B26], [@B32]\]. So far, it is unclear whether histology impacts the outcome of PTCL after salvage autoSCT. In some series ALCL showed a favorable outcome compared to other pathological subtypes \[[@B25], [@B26], [@B30], [@B31]\]. However, the ALK status was not determined in all series and furthermore, Zamkoff et al. could not demonstrate a long-term DFS for recurrent (ALK-negative) ALCL following HDT-autoSCT \[[@B29]\]. The encouraging results for patients with ALCL by Fanin et al., (5-year OS and PFS of 70% and 56%, resp.) were probably biased by age and inclusion of patients in first complete remission (CR), who showed a significantly better outcome in a subgroup analysis \[[@B23]\].

The disease status at the time of transplantation often correlates with the outcome after salvage HDT-autoSCT. In fact, several authors found a better long-term survival in patients transplanted in CR than in patients with other disease status at transplantation \[[@B23], [@B27], [@B32], [@B33], [@B35]--[@B37]\]. Other authors could not confirm this finding in their survey \[[@B24], [@B25], [@B31]\]. However, since all data in this setting are generated retrospectively, the value of this observation needs further observation.

In summary, second-line HDT-autoSCT in PTCL is feasible and seems an effective approach for a considerable subgroup of patients.

2.2. First-Line Therapy {#sec2.2}
-----------------------

Some retrospective studies on upfront HDT-autoSCT have been published and are summarized in [Table 2(a)](#tab2){ref-type="table"} \[[@B38]--[@B43]\]. Like in the salvage setting, a comparison of the cited series is hampered by their variety. Some series reported mainly on patients with a low or intermediate low IPI, whereas others predominantly included patients with an unfavorable prognostic index. In addition, most studies contained patients receiving HDT-autoSCT in second line, but not all of them show a subgroup analysis for the upfront setting. The OS in these retrospective studies ranged from 53% at 3 years to 62--68% at 5 years. Interestingly, the DFS/EFS did not appear to be much lower than the OS in most cohorts that might indicate a substantial curative potential for this approach in previously untreated PTCL. The EBMT (European Group for Blood and Marrow Transplantation) published the largest study in this setting. Kyriakou et al reported data on 146 patients with angioimmunoblastic T-cell lymphoma (AITL) showing an actuarial OS of 67% at 2 years and 59% at 4 years, respectively, after a median observation of 31 months. About two thirds of the patients were transplanted in first CR or PR. Interestingly, patients who received a TBI- (total body irradiation-) based conditioning regimen had a significantly lower relapse rate in this study \[[@B41]\].

In these retrospective studies chemotherapy-sensitive disease was the major factor predicting OS and PFS \[[@B39]--[@B41], [@B43]\]. Patients transplanted in CR or PR showed a superior long-term outcome compared to patients with chemotherapy-refractory disease. Other parameters (e.g., age, PIT, IPI) could not consistently be detected as being of prognostic value.

Although mainly showing promising results, the cited retrospective studies are limited by focussing on patients, only, who actually proceed to transplantation leading to superior results due to patient selection.

Prospective randomized PTCL-restricted studies assessing the value of upfront high-dose therapy in PTCL are lacking. Two French trials by the GELA (Groupe d\'Etude des Lymphomes de l\'Adulte) published data on autoSCT as frontline strategy in poor-risk, aggressive NHL, including PTCL \[[@B44]--[@B46]\]. In the LNH87-2 study, patients were treated with either consolidative sequential chemotherapy or HDT-autoSCT \[[@B44], [@B45]\]. The LNH93-3 trial compared a high-dose arm with shortened first-line myeloablative chemotherapy with a sequential consolidation chemotherapy arm. In the intent-to-treat analysis, none of these studies demonstrated a significant benefit for the high-dose arm \[[@B46]\]. In addition, a pooled data matched control analysis failed to show a significant advantage for upfront HDT-autoSCT \[[@B48], [@B47]\]. However, the limited number of patients in the high-dose group and the restriction to high-risk patients, only, do not allow to definitely clarify the impact of first-line HDT-autoSCT in PTCL from these data. In another subgroup analysis, Nickelsen et al. reported results of 33 patients with PTCL from a single-arm study by the German High-Grade Non-Hodgkin Lymphoma Study Group \[[@B49]\]. Patients with high-risk aggressive lymphomas were treated with dose-escalated CHOP plus etoposide necessitating repeated autoSCT. Compared to B-cell NHL, PTCL showed a significantly worse OS and EFS at 3 years in an intent-to-treat analysis.

So far, five larger prospective PTCL-restricted trials have published data on 372 patients with frontline HDT-autoSCT \[[@B51]--[@B54]\]. Compared to the cited retrospective studies, these prospective series are much more homogeneous. The median age ranged between 43 and 57 years, PTCL unspecified; AITL and ALCL accounted for 77 to 100% of all histological subtypes; the age-adjusted IPI was high or intermediate high in 46 to 72%; the most commonly used myeloablative regimen was the BEAM protocol (*n* = 228), and the disease status at transplantation was CR or PR in 59 to 76%. Only one study included ALK-positive ALCL \[[@B51]\]. In these trials the OS ranged from 48 to 73% at 3 years to 34% at 12 years. The DFS/EFS or the progression-free survival (PFS) was between 36 to 53% at 3 years and 30% at 12 years. One consistently found problem of upfront HDT-autoSCT is early progressive disease leading to about one third of patients in intent-to-treat analyses, who finally fail to achieve transplantation. Mercadal et al. reported a still significant lower transplantation rate of 41%. Of note, in this trial poor stem cell mobilization was the second most frequent cause of failing HDT-autoSCT \[[@B52]\].

With regard to these prospective data, again the remission status at the time of transplantation was a significantly prognostic factor in most studies that provided this analysis \[[@B51]--[@B52]\]. In addition, the IPI and PIT also show prognostic value in some \[[@B52], [@B53]\] but not in all series \[[@B50]\]. Other parameters, for example, histological subtype, age, sex, stage have not been concordantly been found to impact the outcome. The prospective series on upfront autoSCT are listed in [Table 2(b)](#tab2){ref-type="table"}.

3. Allogeneic Stem Cell Transplantation {#sec3}
=======================================

In contrast to the cytotoxic effect of HDT-autoSCT, allogeneic SCT (alloSCT) could add a graft-versus-lymphoma (GVL) effect to the myeloablative or reduced intensity conditioning (RIC) regimen, potentially improving the therapeutic outcome. However, the experience with alloSCT for PTCL is limited. To date, no relevant data for the upfront setting are available. Besides some case reports, five retrospective series with at least 10 patients have been reported in patients with relapsing and refractory PTCL ([Table 3(a)](#tab3){ref-type="table"}) \[[@B40], [@B55]--[@B58]\].

The largest series was published by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire. In 77 pretreated patients who mainly had a myeloablative conditioning regimen the 5-year OS and PFS were 57% and 53%, respectively, after a median followup of 43 months. The treatment-related mortality (TRM) was 33% at 5 years. In a multivariate analysis, chemotherapy-resistant disease at transplantation and grade 3/4 acute graft-versus-host disease (GVHD) were the strongest adverse prognostic factors for OS. The TRM was similar in both conditioning groups \[[@B57]\]. Most studies could reveal a GVL effect \[[@B56]--[@B58]\]. However, the TRM/NRM (nonrelapse mortality) had a relevant impact on outcome and was increasing over time up to 69% at 3 years in the series by Hamadani et al. \[[@B56]\]. The OS ranged from 40% at 2 years to 57% at 5 years.

Two prospective studies have been published so far ([Table 3(b)](#tab3){ref-type="table"}) \[[@B59], [@B60]\]. In the Italian phase II trial by Corradini et al. 17 patients underwent RIC and alloSCT as salvage therapy \[[@B59]\]. Eight out of 17 patients had failed front-line HDT-autoSCT. After a median followup of 28 months, 14 of 17 patients were alive. The estimated 3-year OS and PFS rates were 81% and 64%, respectively. The TRM was impressively low with only 6%. Notably, donor lymphocyte infusions given at the time of progression resulted in a disease response in two out of four patients, indicating evidence of a GVL effect. In the German study by Wulf et al. 10 patients were treated with chemotherapy combined with the humanized antiCD52 monoclonal antibody, alemtuzumab, followed by RIC and alloSCT. Two patients had prior HDT-autoSCT. The OS was 70% with six patients in CR after a median followup of 7 months \[[@B60]\].

4. Summary {#sec4}
==========

Due to their generally poor prognosis after conventional chemotherapy more effective treatment strategies in PTCL are urgently needed. Although randomised trials are lacking, HDT-autoSCT can be regarded as feasible and safe in PTCL. In the salvage setting, several subgroup analysis and comparisons show similar results compared to diffuse large-cell B-cell lymphoma. This finding could recently be confirmed by Sohn et al. \[[@B61]\]. Therefore, taken together the existing data, HDT-autoSCT seems a reasonable approach in relapsing and refractory PTCL particularly in those with chemotherapy-sensitive disease.

The value of upfront HDT-autoSCT remains to be definitely established. A recently published retrospective comparison did not find a significant benefit of this strategy compared to conventional treatment \[[@B62]\]. However, in this study the high-dose group was heterogeneous ranging from high-dose CHOP to alloSCT. In contrast, other retrospective studies revealed a significant better outcome when HDT-autoSCT was compared to chemotherapy, alone \[[@B5], [@B36]\]. Taken together, the prospective data mainly show promising results, especially for patients achieving a good remission status prior to transplantation, that has been reported as independent prognostic factor in most series. Therefore, these patients should mainly be regarded as candidates for upfront autoSCT. Since one major obstacle of this approach is early progressive disease, novel treatment concepts incorporating new agents and/or dose-dense regimen should be further investigated to improve remission status prior to transplantation. In a subanalysis of several trials by the DSHNHL (German High-Grade Non-Hodgkin Lymphoma Study Group), the addition of etoposide to the CHOP-protocol improved the outcome in younger patients with PTCL \[[@B63]\]. Furthermore, alemtuzumab has shown efficacy especially in untreated PTCL \[[@B64]--[@B67]\]. However, this agent can cause significant infectious and hematologic toxicities that have led to early closure of some trials \[[@B65]--[@B67]\]. Recently, EBV-associated B-cell lymphomas have been reported complicating alemtuzumab therapy especially when given in higher dosages \[[@B68], [@B69]\]. To better define the role of chemoimmunotherapy in the concept of HDT-autoSCT, the Nordic Lymphoma Group is conducting a multicenter randomized trial using dose-dense chemotherapy induction with or without alemtuzumab.

Allogeneic stem cell transplantation could offer a curative option in younger patients. However, the experience with this approach is sparse and limited to relapsed and refractory PTCL. In the prospective series nonmyeloablative conditioning protocols were used with very encouraging results especially in the Italian study. Furthermore, a GVL effect could be demonstrated. Taken together, the current data support the concept of alloSCT in eligible patients with relapsing chemosensitive PTCL, especially after failing prior HDT-autoSCT.

To further investigate the role of stem cell transplantation in previously untreated PTCL, this year the DSHNHL in cooperation with other groups will initiate a prospective randomised multicenter trial comparing upfront autoSCT versus alloSCT following dose-dense induction chemotherapy.

The author indicated no potential conflicts of interest.

AaIPI:

:   Age-adjusted IPI

ALCL:

:   Anaplastic large cell lymphoma

ALK:

:   Anaplastic lymphoma kinase

AlloSCT:

:   Allogeneic stem cell transplantation

AITL:

:   Angioimmunoblastic T-cell lymphoma

BEAC:

:   BCNU, etoposide, cytarabin, cyclophosphamide

BEAM:

:   BCNU, etoposide, cytarabin, melphalan

BCNU:

:   Carmustine

BEC:

:   Busulfan, etoposide, cyclophosphamide

CR:

:   Complete remission

CVB:

:   BCNU, etoposide, cyclophosphamide

DSF:

:   Disease-free survival

EATL:

:   Enteropathy-associated T-cell lymphoma

EFS:

:   Event-free survival

Eto:

:   Etoposide

IPI:

:   International prognostic index

M:

:   Months

Mel:

:   Melphalan

NK/T:

:   Natural killer-cell/T-cell leukemia/lymphoma

OS:

:   Overall survival

PFS:

:   Progression-free survival

PR:

:   Partial remission

PTCLu:

:   Peripheral T-cell lymphoma, unspecified

Thio:

:   Thiotepa

TRM:

:   Treatment-related mortality

Tx:

:   Transplantation

W:

:   Weeks

Y:

:   Year

CHOEP:

:   Cyclophosphamide, vincristine, doxorubicin, etoposide, prednisone

CTCL:

:   Cutaneous T-cell lymphoma

CVB/CBV:

:   BCNU, etoposide, cyclophosphamide

Cy:

:   Cyclophosphamide

HDT-autoSCT:

:   High-dose therapy with autologous stem cell transplantation

HSTL:

:   Hepatosplenic T-cell lymphoma

MCEC:

:   Ranimustine, cyclophosphamide, etoposide, carboplatin

Mito:

:   Mitoxantrone

TBI:

:   Total body irradiation

AutoSCT:

:   Autologous stem cell transplantation

Ext:

:   Extensive

GVHD:

:   Graft-versus-host disease

Leuk:

:   Leukemia

MA:

:   Myeloablative conditioning

NK:

:   Natural killer cell

NRM:

:   Nonrelapse mortality

RIC:

:   Reduced intensity conditioning

T-PLL:

:   T-cell prolymphocytic leukaemia.

###### 

Studies on high-dose therapy and autologous stem cell transplantation in PTCL as second-line therapy.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Retrospective data                                                                                                                                                  
  ------------------------------- ------ ----- ---- ----------------- ---------------- ---------------------- ----------- --------------- ----------------- --------- -----------------------------------
  Vose et al. \[[@B22]\]          1990   17    33   No data\*         No data          Diverse                CR 42%\     28% (2 y)       35% (2 y)         28        
                                                                                                              PR 26%                                                  

                                                                                                                                                                      

  Fanin et al. \[[@B23]\]         1999   64    25   ALCL 100%         aaIPI\           Diverse                CR 47%      56% (5 y)       70% (5 y)         43        34/64 transplanted 2.line
                                                                      0/1 48%\                                                                                        
                                                                      2/3 22%\                                                                                        
                                                                      Unknown 30%                                                                                     

                                                                                                                                                                      

  Rodríguez et al. \[[@B24]\]     2001   29    43   No data\*         0/1 31%\         Diverse                CR 38%\     32% (3 y)       39% (3 y)         43        
                                                                      2 41%\                                  PR 48%                                                  
                                                                      3 21%\                                                                                          
                                                                      4/5 7%                                                                                          

                                                                                                                                                                      

  Blystad et al. \[[@B25]\]       2001   40    42   PTCLu 50%\        aaIPI\           Diverse                CR 70%\     56% (3 y)       58% (3 y)         25        23/40 transplanted 2.line
                                                    ALCL 35%\         0/1 42%\                                PR 30%                                                  
                                                    Other 15%         2/3 45%\                                                                                        
                                                                      Unknown 13%                                                                                     

                                                                                                                                                                      

  Song et al. \[[@B26]\]          2002   36    46   PTCLu 56%\        No data          Mel/Eto                CR 42%\     37% (3 y)       48% (3 y)         42        
                                                    ALCL 25%\                                                 PR 50%                                                  
                                                    NK/T 11%\                                                                                                         
                                                    Other 8%                                                                                                          

                                                                                                                                                                      

  Rodríguez et al. \[[@B27]\]     2003   115   41   PTCLu 63%\        aaIP\            Diverse                CR 56%\     60% (5 y)\      56% (5 y)\        37        78/115 transplanted 2.line
                                                    ALCL 22%\         0/1 40%\                                PR 38%      49% (5 y)\*\*   45% (5 y)\*\*               
                                                    NK/T 15%          2/3 60%                                                                                         

                                                                                                                                                                      

  Schetelig et al. \[[@B28]\]     2003   29    51   AITL 100%         aaIPI\           Diverse                No data     37% (5 y)\      60% (5 y)\        60        15/29 transplanted 2.line
                                                                      0/1 21%\                                            39% (5 y)\*\*   44% (5 y)\*\*               
                                                                      2/3 79%                                                                                         

                                                                                                                                                                      

  Zamkoff et al. \[[@B29]\]       2004   16    52   ALK^−^ALCL 100%   aaIPI\           Diverse                CR 60%\     12 w (median)   72 w (median)     No data   
                                                                      0/1 67%\                                PR 40%                                                  
                                                                      2/3 33%                                                                                         

                                                                                                                                                                      

  Jantunen et al. \[[@B30]\]      2004   37    46   PTCLu 38%\        0/1 46%\         BEAC/BEAM              CR/PR 87%   44% (5 y)\      54% (5 y)\        24        19/37 transplanted 2.line TRM 16%
                                                    ALCL 38%\         2 22%\                                              28% (5 y)\*\*   45% (5 y)\*\*               
                                                    EATL 14%\         3 19%\                                                                                          
                                                    Other 11%         4/5 14%\                                                                                        
                                                                      Unknown 3%                                                                                      

                                                                                                                                                                      

  Jagasia et al. \[[@B31]\]       2004   28    39   ALCL 57%\         aaIPI\           Cy/Eto/TBI or CBV      CR 39%\     50% (3 y)       69% (3 y)         44        7/28 underwent alloSCT
                                                    PTCLu 21%\        0/1 29%\                                PR 46%                                                  
                                                    AITL 11%\         2/3 50%\                                                                                        
                                                    NK/T 11%          Unknown 21%                                                                                     

                                                                                                                                                                      

  Kewalramani et al. \[[@B32]\]   2006   24    48   PTCLu 58%\        aaIPI\           Diverse                CR 63%\     24% (5 y)       33% (5 y)         72        
                                                    ALCL 17%\         0/1 46%\                                PR 37%                                                  
                                                    AITL 17%\         2/3 54%                                                                                         
                                                    Other 8%                                                                                                          

                                                                                                                                                                      

  Kim et al. \[[@B33]\]           2007   40    44   PTCLu 50%\        aaIPI\           Diverse                CR 28%\     No data         11.5 m (median)   16        29/40 transplanted 2.line
                                                    NK/T 25%\         0/1 45%\                                PR 52%                                                  
                                                    ALCL 13%\         2/3 53%\                                                                                        
                                                    Other 13%         Unknown 3%                                                                                      

                                                                                                                                                                      

  Smith et al. \[[@B34]\]         2007   32    44   ALCL 66%\         aaIPI (at Tx)\   BEC                    No data     18% (5 y)       34% (5 y)         30        26/32 transplanted 2.line
                                                    PTCLu 34%         0/1 72%\                                                                                        
                                                                      2/3 28%                                                                                         

                                                                                                                                                                      

  Chen et al. \[[@B35]\]          2008   53    45   ALCL 34%\         No data          Diverse                CR/PR 89%   25% (5 y)\      48% (5 y)\        60        38/53 transplanted 2.line
                                                    PTCLu 30%\                                                            9% (5 y)\*\*    37% (5 y)\*\*               
                                                    AITL 17%\                                                                                                         
                                                    Other 19%                                                                                                         

                                                                                                                                                                      

  Lee et al. \[[@B36]\]           2008   47    42   NK/T 100%         aaIPI\           CVB/BEAM/ MCEC (72%)   CR 58%      No data         No data           117       33/47 transplanted 2.line
                                                                      0/1 82%\                                                                                        
                                                                      2/3 18%                                                                                         

                                                                                                                                                                      

  Yang et al. \[[@B37]\]          2009   64    44   PTCLu 100%        aaIPI\           BEAM/CVB (70%)         CR 33%\     44% (3 y)\      53% (3 y)\        30        36/64 transplanted 2.line
                                                                      0/1 56%\                                PR 58%      33% (3 y)\*\*   46% (3 y)\*\*               
                                                                      2/3 44%                                                                                         
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group

\*classified according to the Working Formulation

\*\*for the subgroup of patients transplanted 2.line.

###### 

Studies on high-dose therapy and autologous stem cell transplantation in PTCL as first-line therapy.

###### 

\(a\) Retrospective data

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Year   *n*   Age   Histologies (WHO)   IPI           High-dose regimen     Status at Tx   DFS/EFS/ PFS/RFS   OS          Followup (months)   Comment
  ----------------------------- ------ ----- ----- ------------------- ------------- --------------------- -------------- ------------------ ----------- ------------------- ----------------------------------------------------------------
  Rodríguez et al. \[[@B38]\]   2007   19    46    AITL 100%           aaIPI\        BEAM/BEAC (79%)       CR1 42%\       55% (3 y)          60% (3 y)   25                  15/19 transplanted 1.line
                                                                       0/1 37%\                            PR1 26%                                                           
                                                                       2/3 63%                                                                                               

                                                                                                                                                                             

  Rodríguez et al. \[[@B39]\]   2007   74    46    PTCLu 50%\          aaIPI\        BEAM/BEAC (91%)       No data        63% (5 y)          68% (5 y)   67                  
                                                   ALCL 31%\           0/1 35%\                                                                                              
                                                   AITL 11%\           2/3 65%                                                                                               
                                                   Other 7%                                                                                                                  

                                                                                                                                                                             

  Feyler et al. \[[@B40]\]      2007   64    45    PTCLu 47%\          0/1 34%\      Diverse               CR1 48%\       50% (3 y)          53% (3 y)   48                  Incl. CTCL, T-cell leukemia/lymphoma 46/64 transplanted 1.line
                                                   ALCL 31%\           2 11%\                              PR1 23%                                                           
                                                   AITL 8%\            3 11%\                                                                                                
                                                   Other 14%           4/5 2%\                                                                                               
                                                                       Unknown 42%                                                                                           

                                                                                                                                                                             

  Kyriakou et al. \[[@B41]\]    2008   146   53    AITL 100%           No data       BEAM (74%)            CR1 33%\       49% (4 y)          59% (4 y)   31                  101/146 transplanted 1.line
                                                                                                           PR 36%                                                            

                                                                                                                                                                             

  Prochazka et al. \[[@B42]\]   2009   18    59    PTCLu 56%\          0/1 28%\      BEAM                  No data        52% (2 y)          71% (2 y)   26                  
                                                   ALCL 39%\           2 28%\                                                                                                
                                                   AITL 6%             ≥3 44%                                                                                                

                                                                                                                                                                             

  Numata et al. \[[@B43]\]      2010   39    53    PTCLu 31%\          aaIPI\        MCEC (*n* = 32)\      CR1 69%        61% (5 y)          62% (5 y)   78                  23/39 transplanted 1.line
                                                   AITL 28%\           0/1 33%\      TBI-based (*n* = 7)                                                                     
                                                   ALCL 23%\           2/3 59%\                                                                                              
                                                   NK/T 18%            Unknown 8%                                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Studies including both patients receiving HDT-autoSCT 1.line and 2.line are listed in the table representing the predominant group.

###### 

\(b\) Prospective data

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Year   *n*   Age   Histologies (WHO)   IPI        High-dose regimen   Status at Tx    Tx rate   DFS/EFS/ PFS   OS           Followup (months)   Comment
  ----------------------------- ------ ----- ----- ------------------- ---------- ------------------- --------------- --------- -------------- ------------ ------------------- ------------------------------------------
  Mounier et al. \[[@B48]\]     2004   28    36    PTCLu 56%\          0/1 25%\   BEAM/CBV            CR 100%         No data   44% (5 y)      54% (5 y)    78′                 Incl. precursor T-cell lymphoma
                                                   Precursor 44%       ≥2 75%                                                                                                   

                                                                                                                                                                                

  Nickelsen et al. \[[@B49]\]   2009   33    48    ALK^−^ALCL 39%\     aaIPI\     MegaCHOEP           CR 49%\         67%       26% (3 y)      45% (3 y)    53                  Sequential HDT-autoSCT Subgroup analysis
                                                   PTCLu 33%\          0/1 9%\                        PR 6%\                                                                    
                                                   AITL 12%\           2/3 91%                        after therapy                                                             
                                                   Other 16%                                                                                                                    

                                                                                                                                                                                

  Corradini et al. \[[@B51]\]   2006   62    43    PTCLu 45%\          0/1 19%\   Mito/Mel or BEAM    CR 56%\         71%       30% (12 y)     34% (12 y)   76                  Incl. ALK^+^ALCL
                                                   ALK^+^ ALCL 30%\    ≥2 71%                         PR 16%                                                                    
                                                   AITL 16%\                                                                                                                    
                                                   Other 9%                                                                                                                     

                                                                                                                                                                                

  Rodríguez et al. \[[@B50]\]   2007   26    44    PTCLu 42%\          aaIPI\     BEAM                CR 65%\         73%       53% (3 y)      73% (3 y)    35\'                No ALK^+^ALCL 13/26 transplanted 1.line
                                                   ALK^+^ALCL 31%\     0/1 28%\                       PR 8%                                                                     
                                                   AITL 27%            2/3 72%                                                                                                  

                                                                                                                                                                                

  Mercadal et al. \[[@B52]\]    2008   41    47    PTCLu 49%\          0/1 22%\   BEAM/BEAC           CR 49%\         41%       30% (4 y)      39% (4 y)    38                  No ALK^+^ALCL
                                                   AITL 29%\           2 32%\                         PR 10%                                                                    
                                                   HSTL 5%\            3 22%\                                                                                                   
                                                   NK/T 5%\            4/5 24%                                                                                                  
                                                   Other 12%                                                                                                                    

                                                                                                                                                                                

  Reimer et al. \[[@B53]\]      2009   83    47    PTCLu 39%\          aaIPI\     Cy/TBI              CR 47%\         66%       36% (3 y)      48% (3 y)    33                  No ALK^+^ALCL
                                                   AITL 33%\           0/1 49%\                       PR 24%                                                                    
                                                   ALK^−^ALCL 16%\     2/3 51%                                                                                                  
                                                   Other 12%                                                                                                                    

                                                                                                                                                                                

  D\'Amore et al. \[[@B54]\]    2009   160   57    PTCLu 39%\          0/1 18%\   BEAM                No data         71%       49% (3 y)      57% (3 y)    45                  No ALK^+^ALCL
                                                   AITL 19%\           ≥2 72%                                                                                                   
                                                   ALK^−^ALCL 19%\                                                                                                              
                                                   HSTL 13%\                                                                                                                    
                                                   Other 10%                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Studies on High-Dose Therapy and Allogeneic Stem Cell Transplantation in PTCL.

###### 

\(a\) Retrospective data

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Year   *n*   Age   Histologies         IPI          Previous autoSCT   Regimen (MA versus RIC)   Status at Tx   DFS/EFS/ PFS   OS          TRM/NRM   Followup (months)   GVHD
  ----------------------------- ------ ----- ----- ------------------- ------------ ------------------ ------------------------- -------------- -------------- ----------- --------- ------------------- ------------------------
  Feyler et al. \[[@B40]\]      2007   18    28    PTCLu 50%\          0/1 33%\     11%                100% MA                   No data        33% (3 y)      39% (3 y)   38%\*     57                  Acute GVHD °3/4: 28%\
                                                   T-cell leuk. 28%\   ≥2 66%                                                                                                                            Ext. chronic GVHD: 6%
                                                   ALCL 17%\                                                                                                                                             
                                                   CTCL 6%                                                                                                                                               

                                                                                                                                                                                                         

  Murashige et al. \[[@B55]\]   2005   28    38    NK/T 79%\           No data      32%                82% versus 18%            CR 57%         34% (2 y)      40% (2 y)   29%       34                  Acute GVHD °3/4: 29%\
                                                   Blastic NK 11%\                                                                                                                                       Ext. chronic GVHD: 11%
                                                   NK-leukemia 11%                                                                                                                                       

                                                                                                                                                                                                         

  Hamadani et al. \[[@B56]\]    2008   14    43    PTCLu 36%\          aaIPI\       14%                57% versus 43%            CR 21%\        31% (3 y)      35% (3 y)   28%\*     34                  Acute GVHD °3/4: 21%\
                                                   AITL 28%\           0/1 57%\                                                  PR 35%                                                                  Chronic GVHD: 50%
                                                   ALCL 14%\           2/3 42%                                                                                                                           
                                                   NK/T 14%\                                                                                                                                             
                                                   Other 7%                                                                                                                                              

                                                                                                                                                                                                         

  Le Gouill et al. \[[@B57]\]   2008   77    36    PTCLu 35%\          0/1 61%\     25%                74% versus 26%            CR 40%\        53% (5 y)      57% (5 y)   21%\*     43                  Acute GVHD °3/4: 21%
                                                   ALCL 35%\           ≥2 32%\                                                   PR 30%                                                                  
                                                   AITL 14%\           Unknown 6%                                                                                                                        
                                                   Other 16%                                                                                                                                             

                                                                                                                                                                                                         

  Kyriakou et al. \[[@B58]\]    2009   45    48    AITL 100%           No data      33%                56% versus 45%            CR 27%\        53% (3 y)      64% (3 y)   18%\*     29                  Acute GVHD °3/4: 11%\
                                                                                                                                 PR 22%                                                                  Ext. chronic GVHD: 24%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

\(b\) Prospective data

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                        Year   *n*   Age   Histologies   IPI        Previous autoSCT   Regimen (MA versus RIC)   Status at Tx   DFS/EFS/ PFS   OS          TRM/NRM   Followup (months)   GVHD
  ----------------------------- ------ ----- ----- ------------- ---------- ------------------ ------------------------- -------------- -------------- ----------- --------- ------------------- ------------------------
  Corradini et al. \[[@B59]\]   2004   17    41    PTCLu 53%\    aaIPI\     47%                100% RIC                  CR 12%\        64% (3 y)      81% (3 y)   6%        28                  Acute GVHD °3/4: 12%\
                                                   ALCL 24%\     0/1 24%\                                                PR 71%                                                                  Ext. chronic GVHD: 6%
                                                   AITL 24%      2/3 76%                                                                                                                         

                                                                                                                                                                                                 

  Wulf et al. \[[@B60]\]        2005   10    45    PTCLu 40%\    No data    20%                100% RIC                  CR 10%\        60% (7 m)      70% (7 m)   30%       7                   Acute GVHD °3/4: 10%\
                                                   ALCL 30%\                                                             PR 50%                                                                  Ext. chronic GVHD: 50%
                                                   AITL 20%\                                                                                                                                     
                                                   T-PLL 10%                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*at day 100.

[^1]: Academic Editor: Brian Bolwell
